Rate My Professor Xuexia Wang

Dr. Wang specializes in developing statistical methods and computational tools for genetic discovery and risk prediction, with a focus on identifying genetic factors for cancer and treatment-related adverse outcomes, such as anthracycline-related cardiomyopathy. Her research also addresses complex diseases like autism, schizophrenia, and glaucoma, particularly in admixed populations. She has published over 50 peer-reviewed articles, cited approximately 3,000 times, including "Gene-based Association Tests Using GWAS Summary Statistics and Incorporating eQTL" (Scientific Reports, 2022), "TS: a powerful truncated test to detect novel disease associated genes using publicly available GWAS summary data" (BMC Bioinformatics, 2020), "Association of GSTM1 null variant with anthracycline-related cardiomyopathy after childhood cancer—A Children's Oncology Group ALTE03N1 report" (Cancer, 2020), "CELF4 variant and Anthracycline-related Cardiomyopathy – A COG Study (ALTE03N1)" (Journal of Clinical Oncology, 2016), and "Hyaluronidase synthase 3 (HAS3) variant and Anthracycline-related Cardiomyopathy – A report from the Children’s Oncology Group" (Journal of Clinical Oncology, 2014). Dr. Wang has obtained extramural funding totaling $8 million across her career and has been affiliated with $938,017 in funded research as PI, Co-PI, or subcontract PI. She has taught numerous graduate- and undergraduate-level courses in statistics, statistical genetics, and computational statistics, and advised over 20 graduate and undergraduate students.